bpc-157 bioavailability oral vs subcutaneous injection

https://drcosta.com/wp-content/uploads/2022/10/banner-lymphatic-drainage-1.jpg GLOW [Our] basic thinking on AOD9604 is that the drug failed because it was made orally available, which likely reduced bioavailability and also potentially resulted in protein denaturisation in the gastrointestinal tract, which would have reduced the drug’s activity Volume:10mg – 5 vial lab pack (Save 5%) BPC-157 – OLYMPEX SOLUTIONS

20 styles · Sort: Featured